These findings suggest that AD pathology consumes C3 in the AD brain resulting in lower plasma levels; the demonstration that C3‐deficient APP transgenic mice displayed increased Aβ burden at 17 months compared to C3‐sufficient APP mice supports this mechanism.47 The gene discussed is APP; the disease is Alzheimer disease.